Healthcare / BiotechnologyASX
$0.14
+0.01 (+7.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-6.6M · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-61.6%
↓Gross Margin
100.0%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.6%
FCF CAGR
—
FCF margin
-690.8%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $960389.0 · net income $-8.1M · FCF $-6.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $960389.00 | $960389.00 | $892143.00 | $730340.00 | $1.5M |
| Net Income | $-8.1M | $-8.1M | $-6.4M | $-6.2M | $-5.0M |
| EBITDA | $-10.0M | $-10.0M | $-8.4M | $-8.3M | $-4.6M |
| EPS | -0.06 | -0.06 | -0.05 | -0.05 | -0.05 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -1105.7% | -1105.7% | -1022.8% | -1207.1% | -464.5% |
| Net Margin | -844.9% | -844.9% | -714.7% | -845.7% | -333.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.01 | — |
| Current Ratio | 3.22 | 3.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.6M | $-6.6M | $-6.0M | $-6.9M | $-3.7M |
| Returns | |||||
| ROE | -61.6% | -61.6% | -67.7% | -73.7% | -146.5% |
| Valuation | |||||
| P/B | 1.48 | 1.48 | 11.63 | 12.23 | 25.50 |
| Growth & Yield | |||||
| Revenue Growth | 7.6% | 7.6% | 22.2% | -51.0% | — |
| EPS Growth | -18.5% | -18.5% | 5.2% | -13.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-63.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → -0.06
Residual
-63.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.